This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Modelling
A Markov model with monthly cycles was undertaken to access the cost outcomes associated with each programme.
Outcomes assessed in the review
The outcome assessed in the review was the baseline prevalence of C. trachomatis.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
MEDLINE was searched for articles published between 1970 and 1999.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two primary studies were included in the review.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The baseline prevalence of C. trachomatis was 4%.
Methods used to derive estimates of effectiveness
Three questionnaires were developed in order to derive the estimates of effectiveness. These questionnaires were sent to five physicians who represented the opinion leaders in their field.
Estimates of effectiveness and key assumptions
The proportion of 15-to 19-year-olds tested for C. trachomatis due to the presence of symptoms was 10%. The proportion of 20-to 24-year-olds was 15%.
The probability of being tested in a swab-based screening programme, or diagnostically, due to the presence of symptoms was 30% for the 15 -19 age group and 50% for the 20 -24 age group. The probability of being tested in a urine-based screening or diagnostic programme was 70% for the 15 -19 age group and 75% for the 20 -24 age group.
The sensitivity of diagnostic testing was 70% with antigen detection or NAH, 85% with a urine-based NAA, and 95% with a swab-based NAA. The probability was: 30% for symptomatic C. trachomatis; 35% for symptomatic pelvic inflammatory disease (PID); 50% for C. trachomatis spontaneously clearing; 95% for being tested for C. trachomatis or PID if there were symptoms; 95% for the successful treatment of C. trachomatis or PID; and 20% for C. trachomatis cases being detected, treated and reported.
Measure of benefits used in the economic analysis
The measures of health benefit used in the analysis were the number of cases of C. trachomatis, PID, chronic pelvic pain, ectopic pregnancy, infertility and neonatal complications that occurred annually for each programme. These were estimated from the Markov model.
Direct costs
The direct costs included in the study were for the antigen detection tests, the NAA tests, the professional fees for the swab-based and urine-based screening tests, treatment for confirmed C. trachomatis, and the costs associated with treating PID (inpatients and outpatients). Medication costs were also included. These were estimated by adding a 10% mark up and a dispensing fee ($6.11) to the price listed in the Ontario Drug Benefit formula. The total cost for diagnostic testing and screening included both the physician fees and the laboratory costs. The costs of handling the swab and urine samples were also included.
Statistical analysis of costs
A statistical analysis was not performed.
Indirect Costs
The indirect costs included in the study were for ectopic pregnancy, chronic pelvic pain, neonatal conjunctivitis, paediatric pneumonia, paediatric asthma and the lifetime costs of infertility treatment.
Currency
Canadian dollars (Can$).
Sensitivity analysis
A sensitivity analysis was performed on the following variables: the level of participation in the screening programme; the monthly risk of a C. trachomatis infection; the length of the C. trachomatis infectious period; the discount rate used for future health costs and effects;
